Hormone replacement therapy and cardiovascular risk;Risque cardiovasculaire et traitement hormonal substitutif de la menopause

Therapie

Volumn 54, Issue 3, 1999, Pages 375-380

  Plu Bureau, G ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cardiovascular risk; Epidemiology; Hormone replacement therapy; Menopause; Thromboembolism

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM;

EID: 0032857780     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
2. Bureau D, Plu-Bureau G, Thalabard JC. L'évaluation économique des traitements médicaux: méthodes et enjeux. Economie et Statistiques 1993; 266: 65-75.
3. Bouvier-Colle MH, Vallin J, Hatton F. Mortalité et causes de décès en France. Paris: INSERM Doin, 1990.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
5. Scarabin PY, Plu-Bureau G. Evaluation quantitative du risque cardiovasculaire associé au traitement hormonal substitutif de la ménopause. Arch Mal Cœur 1993; 86: 243-248.
6. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79: 647-650.
7. Oger E, Scarabin PY. Traitement hormonal substitutif de la ménopause et risque d'accident vasculaire cérébral. Annales d'endocrinologie 1999 (sous presse).
8. Douketis JD, Ginsberg JS, Holbrook A et aL A reevaluation of the risk of venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997; 157: 1522-1530.
9. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs and Aging 1999 (in press).
10. Pérez-Gutthann S, Garcia-Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
11. Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
12. Grodstein F, Stampfer MJ, Goldhaber SZ et aL Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
13. Writing group for the Pepi trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
14. The writing group for the estradiol clotting factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-480.
15. Emperauger B, deLignières B, Kuttenn F. Estrogènes, progestérone, cœur et vaisseaux. In: Hittinger L, Berthezènz F, Castaigne A et al., eds. Hormones Cœur et vaisseaux. Paris: INSERM 1997.
16. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost 1997; 78: 765-769.
17. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
18. Matthews KA, Kuller LH, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than non users? Am J Epidemiol 1996; 143: 971-978.
19. The coronary drug project research group. Influence of adherence to treatment and the response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1033-1041.
20. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
21. Powles T, Eeles R, Ashley S, Easton D, Chang J et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
22. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
23. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.